BiotechTube

TX000045- Dose A + TX000045- Dose B + Placebo

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pulmonary Hypertension

Conditions

Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

Trial Timeline

Sep 4, 2024 → Nov 20, 2026

NCT ID
NCT06616974

About TX000045- Dose A + TX000045- Dose B + Placebo

TX000045- Dose A + TX000045- Dose B + Placebo is a phase 2 stage product being developed by Tectonic Therapeutic for Pulmonary Hypertension. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06616974. Target conditions include Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction.

What happened to similar drugs?

20 of 20 similar drugs in Pulmonary Hypertension were approved

Approved (20) Terminated (1) Active (0)
✅MonteplaseEisaiApproved
✅lysozyme 90 mg + PlaceboEisaiApproved
✅tadalafil and ambrisentan upfront combination therapyEli LillyApproved
✅Arformoterol tartrate + Placebo: Normal SalineSumitomo PharmaApproved
✅Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
✅Nebulized arformoterol + SalmeterolSumitomo PharmaApproved
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06616974Phase 2Recruiting

Competing Products

20 competing products in Pulmonary Hypertension

See all competitors
ProductCompanyStageHype Score
AP01Avalyn PharmaceuticalsPhase 2
32
macitentan 10 mgBML, Inc.Phase 3
32
tadalafil + tadalafilEli LillyPhase 3
40
CS1 AdministrationCereno ScientificPhase 2
29
CS1Cereno ScientificPre-clinical
24
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
25
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 1
19
LTI-03 + PlaceboRein TherapeuticsPhase 2
32
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
39
DS-1040b + Placebo + EnoxaparinDaiichi SankyoPhase 1/2
32
DS-9231 + PlaceboDaiichi SankyoPhase 2
27
RegadenosonAstellas PharmaPre-clinical
18
Reldesemtiv + PlaceboAstellas PharmaPhase 2
35
MonteplaseEisaiApproved
43
lysozyme 90 mg + PlaceboEisaiApproved
43
Prednisolone + VoriconazoleCiplaPhase 2/3
38
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)Eli LillyPhase 2
35
tadalafil and ambrisentan upfront combination therapyEli LillyApproved
43
Tadalafil- Tablet or Oral suspensionEli LillyPhase 1/2
32